IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract by Angela C. Burman, Tatjana Banovic,

Slides:



Advertisements
Similar presentations
Recombinant CD95-Fc (APG101) prevents graft-versus-host disease in mice without disabling antitumor cytotoxicity and T-cell functions by Natalie Hartmann,
Advertisements

Reduced Graft-versus-Host Disease in C3-Deficient Mice Is Associated with Decreased Donor Th1/Th17 Differentiation  Qing Ma, Dan Li, Roza Nurieva, Rebecca.
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease by Tangsheng Yi, Ying Chen, Lin Wang,
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.
Secondary Lymphoid Organs Contribute to, but Are Not Required for the Induction of Graft-versus-Host Responses following Allogeneic Bone Marrow Transplantation:
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease  Robert Zeiser,
Lung parenchyma-derived IL-6 promotes IL-17A–dependent acute lung injury after allogeneic stem cell transplantation by Antiopi Varelias, Kate H. Gartlan,
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers by Andrea.
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but.
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Differential Effects of Gut-Homing Molecules CC Chemokine Receptor 9 and Integrin-β7 during Acute Graft-versus-Host Disease of the Liver  Alina Schreder,
CCR2 is required for CD8-induced graft-versus-host disease
Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease by Yi Zhang, Ashley R. Sandy, Jina Wang,
Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.
by Yoshinobu Maeda, Pavan Reddy, Kathleen P
Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte.
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.
by Norman Nausch, Ioanna E
Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.
Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease by Tomomi Toubai, Yaping Sun, Isao Tawara, Ann Friedman,
Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation by Christoph Bucher, Lisa Koch, Christine.
B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality by Rachelle G. Veenstra, Ryan Flynn, Katharina.
LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice  Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.
A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome  Gerhard C. Hildebrandt, Krystyna.
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease by Shan He, Fang.
Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor MIP-1α (CCL3) after allogeneic BMT in mice by Angela Panoskaltsis-Mortari,
by Sheng F. Cai, Xuefang Cao, Anjum Hassan, Todd A
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)  Yehudith Azar, Reut.
by Oleg I. Krijanovski, Geoffrey R. Hill, Kenneth R
Graft-Versus-Leukemia Effect and Graft-Versus-Host Disease Can Be Differentiated by Cytotoxic Mechanisms in a Murine Model of Allogeneic Bone Marrow Transplantation.
Evelyn C. Nieves, Tomomi Toubai, Daniel C
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Tatjana Banovic, Kelli P. A. MacDonald, Kate A. Markey, Edward S
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease by Tangsheng Yi, Dongchang Zhao, Chia-Lei.
Volume 15, Issue 6, Pages (June 2014)
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels  Chien-Chun Steven.
Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.
Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice  Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation  Isabel Barao, Maite.
T helper17 Cells Are Sufficient But Not Necessary to Induce Acute Graft-Versus-Host Disease  Cristina Iclozan, Yu Yu, Chen Liu, Yaming Liang, Tangsheng.
Absence of Cutaneous TNFα-Producing CD4+ T Cells and TNFα may Allow for Fibrosis Rather than Epithelial Cytotoxicity in Murine Sclerodermatous Graft-Versus-Host.
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease  Isao Tawara,
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice  Dapeng Wang, Yu Yu, Kelley Haarberg,
Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease  Haruko Sugiyama,
Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction  Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.
Interleukin 17 Is Not Required for Autoimmune-Mediated Pathologic Damage during Chronic Graft-versus-Host Disease  Xiao Chen, Rupali Das, Richard Komorowski,
Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT by Kate H. Gartlan, Antiopi Varelias,
Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses  Axel Kallies, Annie Xin, Gabrielle T.
CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease  Philip R Streeter,
Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation  Jian-Ming Li, Edmund K.
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G
IAPs protect host target tissues from graft-versus-host disease in mice by Tomomi Toubai, Corinne Rossi, Katherine Oravecz-Wilson, Chen Liu, Cynthia Zajac,
Volume 2, Issue 2, Pages (February 2008)
Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect  Shawn G Clouthier,
Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice  Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.
IL-17A mediates cutaneous GVHD
Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplantation by Kate A. Markey, Tatjana.
Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.
Presentation transcript:

IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract by Angela C. Burman, Tatjana Banovic, Rachel D. Kuns, Andrew D. Clouston, Amanda C. Stanley, Edward S. Morris, Vanessa Rowe, Helen Bofinger, Renae Skoczylas, Neil Raffelt, Olivier Fahy, Shaun R. McColl, Christian R. Engwerda, Kelli P. A. McDonald, and Geoffrey R. Hill Blood Volume 110(3):1064-1072 August 1, 2007 ©2007 by American Society of Hematology

Donor-derived IFNγ prevents GVHD independently of effects on donor cells. Donor-derived IFNγ prevents GVHD independently of effects on donor cells. Splenocytes from G-CSF–mobilized wt, IFNγ−/−, and IFNγR−/− B6 donors were transplanted into irradiated (1100 rad) B6D2F1 recipients (n = 18 per group). TCD splenocytes from IFNγ−/− donors were transplanted into B6D2F1 recipients (n = 10) as non-GVHD controls. Data pooled from 2 identical experiments. (A) Survival determined by Kaplan-Meier analysis. #P < .001, recipients of IFNγ−/− versus wt donor grafts and IFNγR−/− versus wt. (B) GVHD clinical scores were determined as a measure of GVHD severity in surviving animals. #P < .001, recipients of IFNγ−/− versus wt donor grafts and IFNγR−/− versus wt. **P < .01 and *P < .05, recipients of wt grafts versus IFNγR−/− donor grafts. Data expressed as means ± standard error (SE). (C) Semiquantitative histopathology and representative images (100 ×) of lung 14 days after BMT in recipients of wt (n = 7), IFNγ−/− (n = 8), and IFNγ−/− TCD grafts (n = 4). Data expressed as means ± SE of individual animals. ***P < .001, wt versus IFNγ−/− grafts. (D) TNFα and IFNγ levels in sera of recipients of wt (n = 10), IFNγ−/− (n = 10), and IFNγ−/− TCD (n = 4) grafts 7 days after SCT. Data expressed as means ± SE of individual animals. ND indicates not detected. #P < .001, wt versus IFNγ−/− grafts. (E) Donor CD4 and CD8 T-cell expansion and proportions of apoptosis within spleen of recipients of wt (n = 8) and IFNγ−/− (n = 9) grafts 14 days after SCT. Data expressed as means ± SE of individual animals. #P < .001, **P < .01. Angela C. Burman et al. Blood 2007;110:1064-1072 ©2007 by American Society of Hematology

The detrimental effects of IFNγ are mediated through the donor T cell. The detrimental effects of IFNγ are mediated through the donor T cell. TCD splenocytes from G-CSF–mobilized wt or IFNγR−/− donors were added to purified wt or IFNγR−/− T cells (n = 10 per group) and transplanted into irradiated (1100 rad) B6D2F1 recipients. TCD splenocytes from wt donors were transplanted into B6D2F1 recipients (n = 3) as non-GVHD controls. (A) Survival determined by Kaplan-Meier analysis. *P < .05 recipients of wt TCD splenocytes plus wt T cells and IFNγR−/− TCD splenocytes plus wt T-cell grafts versus wt TCD splenocytes plus IFNγR−/− T cells and IFNγR−/− TCD splenocytes plus IFNγR−/− T cells. (B) GVHD clinical scores were determined as a measure of GVHD severity in surviving animals **P < .01 recipients of wt TCD splenocytes plus wt T cells and IFNγR−/− TCD splenocytes plus wt T-cell grafts versus wt TCD splenocytes plus IFNγR−/− T cells and IFNγR−/− TCD splenocytes plus IFNγR−/− T cells. (C) Donor CD4+ and CD8+ T cells were quantified 12 days after SCT in B6D2F1 recipients of either wt TCD plus wt T cells (□; n = 6) or wt TCD plus IFNγR−/− T cells (■; n = 6). *P < .05. (D) Levels of TNFα, IFNγ, and IL-5 were determined by cytokine bead array from sera 7 days after transplant. Data expressed as means plus or minus SE of individual animals (n = 9-10 in allogeneic groups, n = 3 in TCD). *P < .05, #P < .001 versus relevant control group. Angela C. Burman et al. Blood 2007;110:1064-1072 ©2007 by American Society of Hematology

The protective effects of IFNγ are mediated through host tissue. The protective effects of IFNγ are mediated through host tissue. Balb/c donors were mobilized with G-CSF and splenocytes were transplanted into irradiated (1000 rad) wt (n = 15) or IFNγR−/− (n = 20) B6 recipients. TCD splenocytes were transplanted into wt (n = 6) or IFNγR−/− recipients (n = 6) as non-GVHD controls. Data pooled from 2 identical experiments. (A) Survival determined by Kaplan-Meier analysis. #P < .001, IFNγR−/− versus wt recipients. (B) GVHD clinical scores were determined as a measure of GVHD severity in surviving animals. **P < .01, IFNγR−/− versus wt recipients. Data expressed as means ± SE. Angela C. Burman et al. Blood 2007;110:1064-1072 ©2007 by American Society of Hematology

IFNγ prevents the development of idiopathic pneumonia syndrome. IFNγ prevents the development of idiopathic pneumonia syndrome. Tissue was collected at day 9 after transplantation from recipients of G-CSF–mobilized allogeneic or TCD grafts. (A) Semiquantitative histopathology was scored as described in “Materials and methods.” GI tract, *P < .03 (n = 4-5 per group); liver (n = 4-5 per group); skin **P < .01 (n = 11 in T-cell-replete and n = 4 in TCD groups); lung, **P < .01 (n = 6 per group). (B) Representative example of histological pulmonary tissue from wt and IFNγR−/− recipients of T-cell-replete and TCD grafts 9 days after transplantation (100 ×). (C) Donor (H-2Dd+) cellular infiltrate in pulmonary tissue was determined by flow cytometry. Significant increases in donor CD4+ T cells (*P < .02), CD8+ T cells, and F480+ macrophages (**P < .01) were seen in the lungs of IFNγR−/− recipients of T-cell-replete allogeneic grafts compared with wt recipients. Ly6G+ neutrophils were significantly decreased in IFNγR−/− recipients (**P < .01). Data represents mean plus or minus SE cells per right upper lobe of lung. Angela C. Burman et al. Blood 2007;110:1064-1072 ©2007 by American Society of Hematology

Donor T cells from IFNγR−/− recipients are hyperresponsive to alloantigens. Donor T cells from IFNγR−/− recipients are hyperresponsive to alloantigens. Splenocytes from G-CSF–mobilized Balb/c donors were transplanted into irradiated (1000 rad) wt or IFNγR−/− B6 recipients. Analyses were performed 9 days after transplantation. (A) Absolute numbers of donor splenic T cells, CD11b+ monocytes/neutrophils, and B cells (n = 4-5 in allogeneic T-cell-replete and n = 3 in TCD groups). (B) IFNγ, IL-5, and TNFα determined in sera by cytokine bead array. **P < .01 (n = 10-17). (C) Purified donor (H-2Dd+) CD4+ T cells were sort-purified (> 95%) from wt or IFNγR−/− recipients and restimulated with purified DCs. IL-5 and IL-4 were measured in supernatants by cytokine bead arrays, while IFNγ was measured by ELISA. Data are means plus or minus SE of triplicate wells and is 1 of 3 representative experiments is shown. ND indicates not detected. (D) Purified donor CD8+ (H-2Dd+) T cells were sort-purified (> 95%) from wt or IFNγR−/− recipients and used as effectors in 51Cr-release CTL assays against host-type EL4 targets and donor-type A20 targets. Data represent means plus or minus SE of triplicate wells combined from 2 replicate experiments. ***P < .001, wt antihost versus IFNγR−/− antihost. Angela C. Burman et al. Blood 2007;110:1064-1072 ©2007 by American Society of Hematology

IFNγ differentially controls IPS and GVHD of the GI tract by direct signaling through nonhematopoietic host tissue. IFNγ differentially controls IPS and GVHD of the GI tract by direct signaling through nonhematopoietic host tissue. (A) Mixed chimeric mice were generated by transplanting wt or IFNγR−/− bone marrow into irradiated (1000 rad) wt or IFNγR−/− recipients as described in “Materials and methods.” After 3 months, these chimeric mice were phenotyped using CD45.1/CD45.2 disparity to ensure APCs (F4/80+ macrophages, CD19+ B cells, and CD11c+ DCs) had fully reconstituted as donor within lung tissue. The mixed chimeric B6 mice were then used as recipients (conditioned with 950 rad total body irradiation and given transplants of G-CSF–mobilized Balb/c donor splenocytes). In some cases, TCD splenocytes were transplanted as non-GVHD controls. (B) Representative lung (top) or GI tract (bottom) in the recipient chimeras (100 ×). (C) Semiquantitative histologic analysis of transplant chimera recipients as described in “Materials and methods.” Data represent mean plus or minus SE of individual animals combined from 2 replicate experiments. n = 6-15 in T-cell–replete groups and n = 4-7 in TCD groups. ***P < .001, wt → wt and IFNγR−/− → wt versus wt → IFNγR−/− and IFNγR−/− → IFNγR−/− as shown. ND indicates no pathology detected. Angela C. Burman et al. Blood 2007;110:1064-1072 ©2007 by American Society of Hematology

Host-derived nitric oxide synthase and IDO do not contribute to IPS Host-derived nitric oxide synthase and IDO do not contribute to IPS. (A) iNOS, eNOS, and IDO transcript levels were determined by real-time PCR in lungs from wt and IFNγR−/− recipients of allogeneic Balb/c grafts 3 days after SCT. Results normalized to β2 m... Host-derived nitric oxide synthase and IDO do not contribute to IPS. (A) iNOS, eNOS, and IDO transcript levels were determined by real-time PCR in lungs from wt and IFNγR−/− recipients of allogeneic Balb/c grafts 3 days after SCT. Results normalized to β2 microglobulin and expressed as means ± SE of duplicates from individual animals (n = 3 per group). (B) Semiquantitative lung histology in wt and iNOS−/− recipients or wt and eNOS−/− recipients of Balb/c grafts 9 days after SCT (n = 8 per group). Non-GVHD controls received TCD grafts (n = 4). A cohort of wt recipients of allogeneic T-cell–replete grafts were implanted with slow release pellets containing the IDO inhibitor 1-MT or vehicle as described in “Materials and methods” (n = 9 per group). Non-GVHD controls received TCD grafts in conjunction with slow release pellets containing 1-MT (n = 3). ND indicates no pathology detected. Data expressed as means plus or minus SE of individual animals, combined from 2 experiments. (C) Representative hematoxylin and eosin–stained images of lung venules from wt and IFNγR−/− recipients given transplants of T-cell–replete grafts demonstrating leukocyte adhesion and migration across the endothelium in the IFNγR−/− recipients (400 ×). (D) Quantitative analysis of leukocyte adhesion and transmigration within lung venules in wt and IFNγR−/− recipients of T-cell–replete or TCD grafts (n = 5-6 per group). Data are means plus or minus SE of individual animals where the mean number of adherent and transmigrating leukocytes was determined in 10 venules per lung. **P < .01, wt versus IFNγR−/− recipients. (E) Purified donor (H-2Dd+) CD4+ T cells were sort-purified (> 95%) from the lungs of wt (□) or IFNγR−/− (■) recipients and restimulated with purified allogeneic DCs. Proliferation was determined by 3H incorporation 60 hours later and IFNγ, IL-5, and IL-4 were measured in supernatants by cytokine bead array. Data are means plus or minus SE of triplicate wells and is 1 of 2 replicate experiments. ND indicates not detected. Angela C. Burman et al. Blood 2007;110:1064-1072 ©2007 by American Society of Hematology